Navigation Links
Ronald DePinho, M.D., selected for prestigious Agilent Technologies Thought Leader Award
Date:3/29/2013

HOUSTON Pancreatic cancer is one the deadliest and hardest to treat cancers. In recognition of his leadership of an innovative translational research program targeted at pancreatic cancer, Ronald DePinho, M.D., president of The University of Texas MD Anderson Cancer Center, was selected for the prestigious Agilent Thought Leader Award.

The Thought Leader Award recognizes researchers whose discoveries represent fundamental advances in the life sciences. DePinho, one of only three awardees in 2012, was selected for his research into pancreatic cancer metabolomics. To further promote DePinho's work, the award provides instrumentation and support to examine the metabolic flux that occurs in the earliest stages of the cancer.

Metabolomics analyzes the physiology of the cell, providing a snapshot of cellular energy stores, as well as metabolic precursors and products. Unlocking and targeting the secrets of the cancer metabolism is a powerful therapeutic strategy, as metabolism is a critical cellular process inherent to cancer cell survival.

DePinho's lab recently reported in the journal Cell a study that leverages metabolomic and transcriptome analysis. This work was the first to link a genetic mutation in the Kras gene to both pancreatic cancer initiation and the subsequent manipulation of metabolic pathways that support tumor growth and progression.

Altered cellular metabolism has long been acknowledged as a hallmark of cancer, but until recently technology couldn't identify discrete and targetable metabolic transformations, aberrations unique to cancer cells. Cancer cells have radically different metabolic properties from the tissue of origin. They require more energy and cellular building blocks to support not only rapid growth, but also survival, as they face harsh conditions from cellular assaults.

DePinho's research group, along with scientists from MD Anderson's Institute for Applied Cancer Science (IACS), will employ the Agilent's instrumentation and software provided to uncover in an unbiased manner alterations in metabolic flux that occur in pancreatic cancer. These discoveries may lead to the identification of biomarkers for the early detection of pancreatic cancer and serve as the basis for developing novel drugs. In fact, IACS currently has multiple metabolism-centric drug discovery programs under way, which will be enhanced by the increased capabilities in metabolomics.

"I'm honored to receive this award," says DePinho. "I've had a long-standing focus on pancreatic cancer, as it remains one of the most difficult to treat cancers due to the lack of effective therapeutic strategies. This technology will allow us to rapidly identify new targets that drive its formation, progression and maintenance, which will translate into clinical advances."


'/>"/>

Contact: Hilary Graham
hngraham@mdanderson.org
713-794-4383
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. UT MD Anderson President Ronald DePinho elected to National Academy of Sciences
2. Renowned Cosmetic and Plastic Surgeon, Ronald L. Moy, M.D. to Present at Upcoming AACS Meeting on TriPollar, a Breakthrough in Radio Frequency Technology
3. California Body Care Supports USO Tribute Show at Ronald Reagan Library
4. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
5. ASH awards Timothy J. Ley, M.D., with 2012 E. Donnall Thomas Lecture and Prize
6. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
7. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
8. Penn Medicines Daniel J. Rader, M.D., receives AHAs Clinical Research Prize
9. Richard Mayeux, M.D., M.S., elected Fellow of AAAS
10. Corita Grudzen, M.D., named a practice change leader to improve health care for older adults
11. Tripp, D.O, F.A.C.O.O.G., Adelstein, D.O, F.A.C.O.O.G., MacFarlane, M.D., F.A.C.O.G., Vardo, D.O, F.A.C.O.G., & Abisla, A.N.P., Receive InTone Specialist Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... This morning, more ... Trump expressing their support for an independent Vaccine Safety Commission. Five of the ... medical journalist, will hold a press conference at 9:00 AM Friday, March ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up to 36% ... other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors ... finding more effective treatment options, the San Diego Gamma Knife Center offers ...
(Date:3/29/2017)... ... March 30, 2017 , ... Grass pollen is the main cause of hay fever in ... The season for grass pollen runs from May to July each year; with the worst ... to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
(Date:3/29/2017)... Baton Rouge, Louisiana (PRWEB) , ... March 29, ... ... trademarked HeartBoost in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, ... campaign at Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global energy-based aesthetic devices market to ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... -- Global intravenous (IV) iron and oral iron market is ... a CAGR of 5%. Iron drugs are ... anemia or other iron deficiencies. Oral iron supplements are recommended ... some cases, oral administrations are not capable of maintaining the ... comes into the picture. Global Intravenous (IV) Iron ...
Breaking Medicine Technology: